

CORRECTED VERSION

(19) World Intellectual Property
Organization
International Bureau



WIPO | PCT



(10) International Publication Number
WO 2013/138568 A8

(43) International Publication Date
19 September 2013 (19.09.2013)

- (51) International Patent Classification:
C07D 487/04 (2006.01) *A61P 3/06* (2006.01)
A61K 31/5025 (2006.01)
- (21) International Application Number:
PCT/US2013/031250
- (22) International Filing Date:
14 March 2013 (14.03.2013)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
61/612,063 16 March 2012 (16.03.2012) US
- (71) Applicant: **VITAE PHARMACEUTICALS, INC.**
[US/US]; 502 West Office Center Drive, Fort Washington,
PA 19034 (US).
- (72) Inventors: **DONG, Chengguo**; 96 Arthur Avenue, Staten
Island, NY 10305 (US). **FAN, Yi**; 40 Bittersweet Drive,
Doylestown, PA 18901 (US). **LEFOTHERIS, Katerina**; 92
Richmond Drive, Skillman, NJ 08558 (US). **LOTESTA,
Stephen**; 99 Jennifer Lane, Burlington, NJ 08016 (US).
SINGH, Suresh, B.; 4 Adams Road, Kendall Park, NJ
08824 (US). **TICE, Colin**; 1325 Pinebrook Court, Ambler,
PA 19002 (US). **ZHAO, Wei**; 930 Heritage Drive,
Eagleville, PA 19403 (US). **ZHENG, Yajun**; 605 Giffin
Court, Hockessin, DE 19707 (US). **ZHUANG, Linghang**;
3135 Fox Drive, Chalfont, PA 18914 (US).
- (74) Agents: **DAVIS, Steven, G.** et al.; McCarter & English,
LLP, 265 Franklin Street, Boston, MA 02110 (US).
- (81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,

BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA,
ZM, ZW.

- (84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*

(48) Date of publication of this corrected version:

28 August 2014

(15) Information about Correction:

see Notice of 28 August 2014

(54) Title: LIVER X RECEPTOR MODULATORS

(57) Abstract: Provided herein are novel compounds and pharmaceutically acceptable salts thereof that are liver X receptor modulators. Also provided are compositions comprising compounds of the invention and a carrier. Additionally, use of the compounds herein and methods for treating a disease or disorder associated with the liver X receptor are further described.



WO 2013/138568 A8